Updated time: 2021-11-15 11:32:59
Colorectal cancer (CRC) is an important cancer with rising annual incidence worldwide, leading to significant morbidity and mortality. Addition of new chemotherapeutic and molecular targeted agents improves the treatment outcome, indicating the necessity to develop new drugs.
Statins are well-known HMGR inhibitors to decrease serum cholesterol and the incidence of cardiovascular and cerebrovascular disorders. They have also shown promise for cancer prevention in clinical studies. We first demonstrated statins with a carboxylic acid-containing long chain possessing the structure similar to hydroxamate inhibiting histone deacetylase (HDAC) activity, an attractive target against cancer. To further improve statins’ HDAC inhibition, we designed and synthesized small molecule that potently inhibit HMGR and HDACs simultaneously.
This small molecule was effective to inhibit a variety of human cancer cells but not normal cells. ChIP-on-chip analysis demonstrated that it down-regulated inflammatory and stemness genes and up-regulated tumor suppressor genes. Oral administration of it prevented DSS-induced colitis and AOM/DSS-induced CRC in mice and also inhibited tumor progression of AOM/DSS and ApcMin/+ mice. CRC metastasis to liver and lung and stemness in mouse models were reduced by this small molecule. Furthermore, this small molecule potentiated the efficacy of oxaliplatin in different preclinical CRC models. Its early-pharmacokinetics in rats and in vitro drug metabolism and pharmacokinetics were explored. Our data provide compelling evidence that this small molecule exerts significant therapeutic benefits against CRC in preclinical models and are promising new drugs for CRC treatment.
- Distinct action mechanism could avoid cross-resistance to current therapy.
- Because of low toxicity, this small molecule monotherapy or combination with oxaliplatin is safe and relevant for CRC treatment.
26A-1010619、26A-1011121
US 9,353,061 B2、EP 2874994、TW I455912,US 9,115,116 B2、TW I537280
To prolong the survival of metastatic CRC patients by JMF3086 monotherapy or combination with oxaliplatin.
Jung-Hsin Lin, Ching-Chow Chen, Jim-Ming Fang, Jhih-Bin Chen, Ting-Rong Chen, Tzu-Tang Wei
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

3,5,N-TRIHYDROXY-ALKANAMIDE AND DERIVAIVES: METHOD FOR MAKING SAME AND USE THEREOF